Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
BRISBANE, Calif., Nov. 03, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that the Company’s compensation committee granted five new employees a total of 14,300 shares of common stock options effective on October 28, 2016. The common stock options were granted pursuant to the Company’s 2016 Inducement Equity Incentive Plan. The awards were made pursuant to the NASDAQ Global Market’s inducement grant exception as a component of our new hires' employment compensation. The new employees receiving the options recently joined the Company.
These options vest over four years with 25% of the options vesting on the first anniversary of each employee’s respective vesting commencement date, and 1/48th of the total grant vesting monthly thereafter, subject to continued service through each applicable vesting date. Each of the employees who received an equity award is a non-executive employee.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The Company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure™, a next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing tools used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. Olerup QTYPE® offers speed and precision in real time as a rapid HLA typing tool. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.CareDx.com.
Investor Contact Jamar Ismail, Westwicke Partners T: +1 415-513-1282 [email protected]
